Classic and new animal models of Parkinson's disease
- PMID: 22536024
- PMCID: PMC3321500
- DOI: 10.1155/2012/845618
Classic and new animal models of Parkinson's disease
Abstract
Neurological disorders can be modeled in animals so as to recreate specific pathogenic events and behavioral outcomes. Parkinson's Disease (PD) is the second most common neurodegenerative disease of an aging population, and although there have been several significant findings about the PD disease process, much of this process still remains a mystery. Breakthroughs in the last two decades using animal models have offered insights into the understanding of the PD disease process, its etiology, pathology, and molecular mechanisms. Furthermore, while cellular models have helped to identify specific events, animal models, both toxic and genetic, have replicated almost all of the hallmarks of PD and are useful for testing new neuroprotective or neurorestorative strategies. Moreover, significant advances in the modeling of additional PD features have come to light in both classic and newer models. In this review, we try to provide an updated summary of the main characteristics of these models as well as the strengths and weaknesses of what we believe to be the most popular PD animal models. These models include those produced by 6-hydroxydopamine (6-OHDA), 1-methyl-1,2,3,6-tetrahydropiridine (MPTP), rotenone, and paraquat, as well as several genetic models like those related to alpha-synuclein, PINK1, Parkin and LRRK2 alterations.
Figures
Similar articles
-
Advancement in the modelling and therapeutics of Parkinson's disease.J Chem Neuroanat. 2020 Jan 26;104:101752. doi: 10.1016/j.jchemneu.2020.101752. Online ahead of print. J Chem Neuroanat. 2020. PMID: 31996329 Review.
-
Toxin-induced models of Parkinson's disease.NeuroRx. 2005 Jul;2(3):484-94. doi: 10.1602/neurorx.2.3.484. NeuroRx. 2005. PMID: 16389312 Free PMC article. Review.
-
Animal models of Parkinson's disease: An updated overview.Rev Neurol (Paris). 2015 Nov;171(11):750-61. doi: 10.1016/j.neurol.2015.07.011. Epub 2015 Sep 4. Rev Neurol (Paris). 2015. PMID: 26343921 Review.
-
Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.Cell Tissue Res. 2004 Oct;318(1):215-24. doi: 10.1007/s00441-004-0938-y. Epub 2004 Jul 28. Cell Tissue Res. 2004. PMID: 15503155 Review.
-
Animal models of Parkinson's disease: a gateway to therapeutics?Neurotherapeutics. 2014 Jan;11(1):92-110. doi: 10.1007/s13311-013-0234-1. Neurotherapeutics. 2014. PMID: 24158912 Free PMC article. Review.
Cited by
-
Nanostars Carrying Multifunctional Neurotrophic Dendrimers Protect Neurons in Preclinical In Vitro Models of Neurodegenerative Disorders.ACS Appl Mater Interfaces. 2022 Oct 26;14(42):47445-47460. doi: 10.1021/acsami.2c14220. Epub 2022 Oct 11. ACS Appl Mater Interfaces. 2022. PMID: 36218307 Free PMC article.
-
PGC-1s in the Spotlight with Parkinson's Disease.Int J Mol Sci. 2021 Mar 28;22(7):3487. doi: 10.3390/ijms22073487. Int J Mol Sci. 2021. PMID: 33800548 Free PMC article. Review.
-
aThe characteristics of glucose metabolism in the sulfonylurea receptor 1 knockout rat model.Mol Med. 2019 Jan 7;25(1):2. doi: 10.1186/s10020-018-0067-9. Mol Med. 2019. PMID: 30616503 Free PMC article.
-
Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications.Environ Health Perspect. 2013 Nov-Dec;121(11-12):1245-52. doi: 10.1289/ehp.1306967. Epub 2013 Aug 9. Environ Health Perspect. 2013. PMID: 23933572 Free PMC article. Review.
-
Hyperhomocysteinemia and neurologic disorders: a review.J Clin Neurol. 2014 Oct;10(4):281-8. doi: 10.3988/jcn.2014.10.4.281. Epub 2014 Oct 6. J Clin Neurol. 2014. PMID: 25324876 Free PMC article. Review.
References
-
- Lees AJ, Hardy J, Revesz T. Parkinson’s disease. The Lancet. 2009;373(9680):2055–2066. - PubMed
-
- Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. α-synuclein in Lewy bodies [8] Nature. 1997;388(6645):839–840. - PubMed
-
- Forno LS. Neuropathology of Parkinson’s disease. Journal of Neuropathology and Experimental Neurology. 1996;55(3):259–272. - PubMed
-
- Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell and Tissue Research. 2004;318(1):121–134. - PubMed
-
- Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurology. 2006;5(3):235–245. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
